Related Experiment Videos
[Clinical studies on cefozopran in pediatrics]
1Department of Pediatrics, Takamatsu Red Cross Hospital.
Insights
Cefozopran (CZOP) effectively treated pediatric bacterial infections, including pneumonia, with excellent clinical responses and bacterial eradication in all patients. This antibiotic demonstrated a favorable safety profile, making it a promising option for children.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antibiotic Therapy
Background:
- Acute bacterial infections pose significant health risks in pediatric populations.
- Intravenous antibiotics are crucial for managing severe pediatric infections.
- Cefozopran (CZOP), a novel cephalosporin, was evaluated for its efficacy and safety in children.
Observation:
- Twelve pediatric patients with acute bacterial infections received intravenous Cefozopran (CZOP).
- Infections included acute pneumonia, acute pyothorax, impetigo, and staphylococcal scalded skin syndrome.
- Clinical assessments and microbiological cultures were performed to monitor treatment response.
Findings:
- All 12 patients achieved good or excellent clinical responses to CZOP treatment.
- Bacterial eradication was confirmed for all 10 identified bacterial strains.
- No significant adverse side effects were reported; one patient exhibited eosinophilia.
Implications:
- Cefozopran (CZOP) demonstrates significant potential as a valuable therapeutic agent for pediatric bacterial infections.
- The favorable clinical outcomes and safety profile suggest CZOP's utility in pediatric infectious disease management.
- Further research may solidify Cefozopran's role in treating a spectrum of pediatric bacterial conditions.
Abstract:
Cefozopran (CZOP, SCE-2787) was given intravenously to 12 children with acute bacterial infections including 9 with acute pneumonia, 1 each with acute pyothorax, impetigo and staphylococcal scalded skin syndrome. Good or excellent clinical responses were obtained in all of the 12 patients and bacterial eradications were achieved for all 10 strains identified in these cases. No side effects were noted. Eosinophilia was observed in one case, however. From the above clinical results, it appears that CZOP is a useful antibiotic for treatment of pediatric patients with various bacterial infections.